174 related articles for article (PubMed ID: 24938515)
1. Strong adverse prognostic impact of hyperglycemic episodes during adjuvant chemoradiotherapy of glioblastoma multiforme.
Mayer A; Vaupel P; Struss HG; Giese A; Stockinger M; Schmidberger H
Strahlenther Onkol; 2014 Oct; 190(10):933-8. PubMed ID: 24938515
[TBL] [Abstract][Full Text] [Related]
2. Commentary on "Strong adverse prognostic impact of hyperglycemic episodes during adjuvant chemoradiotherapy of glioblastoma multiforme".
Champ CE; Klement RJ
Strahlenther Onkol; 2015 Mar; 191(3):281-2. PubMed ID: 25487693
[No Abstract] [Full Text] [Related]
3. Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution.
Joo JD; Kim H; Kim YH; Han JH; Kim CY
J Korean Med Sci; 2015 Nov; 30(11):1597-603. PubMed ID: 26539003
[TBL] [Abstract][Full Text] [Related]
4. Metformin influences progression in diabetic glioblastoma patients.
Adeberg S; Bernhardt D; Ben Harrabi S; Bostel T; Mohr A; Koelsche C; Diehl C; Rieken S; Debus J
Strahlenther Onkol; 2015 Dec; 191(12):928-35. PubMed ID: 26329695
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Treatment Tolerance and Factors Associated with Overall Survival in Elderly Patients with Glioblastoma.
Zhang C; Wang X; Hao S; Su Z; Zhang P; Li Y; Song G; Yu L; Wang J; Ji N; Xie J; Gao Z
World Neurosurg; 2016 Nov; 95():77-84. PubMed ID: 27485530
[TBL] [Abstract][Full Text] [Related]
6. A clinical review of treatment outcomes in glioblastoma multiforme--the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival?
Rock K; McArdle O; Forde P; Dunne M; Fitzpatrick D; O'Neill B; Faul C
Br J Radiol; 2012 Sep; 85(1017):e729-33. PubMed ID: 22215883
[TBL] [Abstract][Full Text] [Related]
7. Delay in adjuvant chemoradiation impacts survival outcome in glioblastoma multiforme patients.
Potharaju M; Mathavan A; Mangaleswaran B; Ghosh S; John R
Acta Oncol; 2020 Mar; 59(3):320-323. PubMed ID: 31573367
[No Abstract] [Full Text] [Related]
8. Response to commentary by Champ and Klement: Is a ketogenic diet the solution for the hyperglycemia problem in glioblastoma therapy?
Mayer A; Vaupel P; Struss HG; Giese A; Stockinger M; Schmidberger H
Strahlenther Onkol; 2015 Mar; 191(3):283-4. PubMed ID: 25595495
[No Abstract] [Full Text] [Related]
9. Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme.
Seidlitz A; Siepmann T; Löck S; Juratli T; Baumann M; Krause M
Radiat Oncol; 2015 Aug; 10():172. PubMed ID: 26276734
[TBL] [Abstract][Full Text] [Related]
10. The impact of surgery on the efficacy of adjuvant therapy in glioblastoma multiforme.
Brzozowska A; Toruń A; Mazurkiewicz M
Adv Clin Exp Med; 2015; 24(2):279-87. PubMed ID: 25931361
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy with and without temozolomide in elderly patients with glioblastoma.
Niyazi M; Schwarz SB; Suchorska B; Belka C
Strahlenther Onkol; 2012 Feb; 188(2):154-9. PubMed ID: 22231634
[TBL] [Abstract][Full Text] [Related]
12. Survival improvements with adjuvant therapy in patients with glioblastoma.
Jayamanne D; Wheeler H; Cook R; Teo C; Brazier D; Schembri G; Kastelan M; Guo L; Back MF
ANZ J Surg; 2018 Mar; 88(3):196-201. PubMed ID: 28922698
[TBL] [Abstract][Full Text] [Related]
13. [Results of postoperative radiochemotherapy of glioblastoma multiforme].
Lövey J; Fedorcsák I; Bajcsay A; Sipos L; Mangel L; Kásler M; Bagó A
Magy Onkol; 2013 Dec; 57(4):232-9. PubMed ID: 24353988
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for glioblastoma therapy associated complications.
Ening G; Osterheld F; Capper D; Schmieder K; Brenke C
Clin Neurol Neurosurg; 2015 Jul; 134():55-9. PubMed ID: 25942630
[TBL] [Abstract][Full Text] [Related]
15. Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials.
Balducci M; Fiorentino A; De Bonis P; Chiesa S; Mangiola A; Mattiucci GC; D'Agostino GR; Frascino V; Mantini G; Alitto AR; Colosimo C; Anile C; Valentini V
Strahlenther Onkol; 2013 Nov; 189(11):926-31. PubMed ID: 23974823
[TBL] [Abstract][Full Text] [Related]
16. The influence of hyperglycemia during radiotherapy on survival in patients with primary glioblastoma.
Adeberg S; Bernhardt D; Foerster R; Bostel T; Koerber SA; Mohr A; Koelsche C; Rieken S; Debus J
Acta Oncol; 2016; 55(2):201-7. PubMed ID: 25990634
[TBL] [Abstract][Full Text] [Related]
17. Patterns of care and predictors of adjuvant therapies in elderly patients with glioblastoma: An analysis of the National Cancer Data Base.
Amsbaugh MJ; Yusuf MB; Gaskins J; Burton EC; Woo SY
Cancer; 2017 Sep; 123(17):3277-3284. PubMed ID: 28452053
[TBL] [Abstract][Full Text] [Related]
18. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
Gutenberg A; Bock HC; Reifenberger G; Brück W; Giese A
Acta Neurochir (Wien); 2013 Mar; 155(3):429-35. PubMed ID: 23254891
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide during radiotherapy of glioblastoma multiforme : Daily administration improves survival.
Nachbichler SB; Schupp G; Ballhausen H; Niyazi M; Belka C
Strahlenther Onkol; 2017 Nov; 193(11):890-896. PubMed ID: 28197654
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
